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Background: The symptom of heavy menstrual bleeding (HMB) diminishes quality-of-life for many mid-age
women and imposes substantial societal burden.We investigated our hypothesis that HMB reflects impaired endo-
metrial vasoconstriction due to endometrial glucocorticoid deficiency. Does reversing this deficiency, by short-term
luteal-phase treatmentwith exogenous glucocorticoid (dexamethasone), ameliorate HMB?
Methods: In our Bayesian response-adaptive parallel-group placebo-controlled randomised trial, five pre-
planned interim analyses used primary outcome data to adjust randomisation probabilities to favour doses
providing most dose-response information. Participants with HMB, recruited from Lothian (Scotland) NHS
clinics and via community invitations/advertisements, were aged over 18 years; reported regular 2142 day
menstrual cycles; and had measured menstrual blood loss (MBL) averaging  50 mL over two screening peri-
ods. Identically encapsulated placebo, or one of six Dexamethasone doses (0¢2 mg, 0¢4 mg, 0¢5 mg, 0¢6 mg,
0¢75 mg, 0¢9 mg), were taken orally twice-daily over five days in the mid-luteal phase of three menstrual
cycles. Participants, investigators, and those measuring outcomes were masked to group assignment.
Primary outcome, change in average MBL from screening to ‘treatment’, was analysed by allocated treatment,
for all with data.
Trial Registration: ClinicalTrials.gov NCT01769820; EudractCT 2012003,40598
Findings: Recruitment lasted 29/01/2014 to 25/09/2017; 176 were screened, 107 randomised and 97 pro-
vided primary outcome data (n = 24,5,9,21,8,14,16 in the seven arms, placebo to 1¢8 mg total daily active
dose). In Bayesian normal dynamic linear modelling, 1¢8 mg dexamethasone daily showed a 25 mL greater
reduction in MBL from screening, than placebo (95% credible interval 1 to 49 mL), and probability 0¢98 of
benefit over placebo. Adverse events were reported by 75% (58/77) receiving dexamethasone, 58% (15/26)
taking placebo. Three serious adverse events occurred, two during screening, one in a placebo participant.
No woman withdrew due to adverse effects.
Interpretation: Our adaptive trial in HMB showed that dexamethasone 1¢8 mg daily reduced menstrual blood
loss. The role of dexamethasone in HMBmanagement deserves further investigation.
Funding: UKMRC DCS/DPFS grant MR/J003611/1.
© 2021 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/)Keywords:
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Research in context
Evidence before this study
Amongst otherwise healthy women of reproductive age, the
symptom of heavy menstrual bleeding (HMB), recurring
monthly over many years, as is common, amounts to substan-
tial cumulative individual morbidity. The adverse impact on
quality of life and productivity is all too often underestimated
by health care providers/policymakers.
In routine clinical practice, particularly primary care, first
line treatment for the symptom of HMB is usually medical ther-
apy (hormonal or non-hormonal). There have been no new
medical approaches for HMB since the levonorgestrel-releasing
intrauterine system (LNG-IUS), licensed in 2001. This locally-
delivered hormonal treatment is highly effective in reducing
MBL volume, and also provides contraceptive efficacy if that is
required, but nearly a fifth of new users of LNG-IUS are dissatis-
fied with side-effects (often including unpredictable break-
through bleeding/spotting), and it is unsuitable for women
desiring pregnancy (as are systemic progestin therapies). A
2013 systematic review of non-surgical treatments for HMB
found that non-hormonal medical treatments showed good
percent reductions in MBL volumes, compared to baseline or
placebo i.e. 26% to 54% reduction in blood loss volumes (MBL)
for anti-fibrinolytics, 20% to 52% for non-steroidal anti-inflam-
matory drugs (NSAIDs). However when prescribed for HMB in
routine clinical practice, these treatments are often reported as
insufficiently effective, or to have become ineffective after a
few months. The UK NHS HMB Audit in outpatient gynaecology
clinics (20122013, n = 8183) found that 29% and 33% respec-
tively of patients, first attending with symptom of HMB,
received oral medication and LNG-IUS. It is salient that within
the follow-up year, over half those starting with oral medication
and one third starting with IUS had switched to a different treat-
ment (often surgical).
This might be partly explained by the fact that a conven-
tional entry criterion for trials of HMB treatments is ‘confirma-
tion’ of HMB by objective assessment of baseline menstrual
blood loss volume (MBL), as exceeding 80 mL average over at
least two menstrual periods. In contrast, routine clinical prac-
tice almost never involves assessment of MBL volume, so many
clinic/primary care recipients of these treatments are likely to
have average MBL volumes considerably lower than the thresh-
old for participation in the original research trials.
This highlights that for the debilitating symptom of HMB, as
commonly encountered in clinical care, there is urgent need for
a targeted medical treatment that is effective and acceptable,
and that can be used while seeking to become pregnant. Alter-
native medical treatment options for HMB are needed if surgi-
cal intervention is to be avoided and fertility/ uterus preserved.
Our laboratory studies dissecting potential mechanistic
pathways implicated in the symptom of HMB, suggested
involvement of endometrial glucocorticoid deficiency. We
hypothesised that the symptom of HMB could be ameliorated
by administration of dexamethasone (a well-known cortisol
surrogate) for 5 days in the luteal phase of the menstrual cycle,
a time of endometrial blood vessel differentiation. Given dexa-
methasone is already licensed, there would be no need for
safety/tolerability studies in healthy volunteers, offering the
potential for accelerated translation from pre-clinical to clinical
studies.
A small proof-of-concept animal study of our proposed ther-
apeutic strategy provided highly supportive evidence, so the
next step was a Bayesian adaptive randomised dose-finding
trial of dexamethasone for treatment of HMB in women.
Added value of this study
The DexFEM study (Dexamethasone For Excessive Menstrua-
tion) provides the first evidence of therapeutic benefit of dexa-
methasone in heavy menstrual bleeding. The efficiency gains
provided by the adaptive design enabled, for a given sample
size, investigation of a larger number of potential doses com-
pared to a conventional parallel group design. For dexametha-
sone dose 18 mg daily for 5 days in the luteal phase of each
menstrual cycle, we found a mean reduction in MBL of 25 mL,
consistent with our local endometrial glucocorticoid-deficiency
hypothesis for HMB.
We included women with moderate sized fibroids and used
a 50 mL MBL threshold for eligibility for our trial (rather than
the commonly used 80 mL), so our trial reports treatment effect
for women representative of those seeking clinical care for the
symptom of HMB.
The trial raised no safety concerns but participation involved
only three treatment cycles. It is thus still to be established that
long-term use of dexamethasone treatment with 18 mg daily
dose (but for only 5 days per menstrual cycle), would not
induce the adverse effects known to be associated with chronic
use of glucocorticoids.
Steroids are commonly prescribed in early pregnancy (for
non-pregnancy related conditions) so if a woman with symp-
toms of HMB is seeking to conceive, Dexamethasone could be
considered for amelioration of HMB.
Implication of all available evidence
Our findings support dexamethasone as a safe and effective
medical therapy for HMB, making it a treatment option that
might be welcomed by women who eschew surgical treatment,
experience unacceptable side-effects with hormonal treatment,
or wish to try for pregnancy.
Local delivery options (intra-vaginal/intra-uterine) should
allow a lower dose than oral treatment, so could be considered
to address concerns regarding cumulative glucocorticoid
effects, as well as having the potential to be more convenient
for users.
A further confirmatory trial is warranted to verify the effi-
cacy of 1.8 mg daily dexamethasone dose, to explore treatment
effect by aetiology and to investigate the criticality of timing of
administration of treatment.
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The symptom of heavy menstrual bleeding (HMB) affects 20% to
52% of menstruating UK women [14], and in developing countries
is 4 to 27%, or more in older (multiparous) women [5]. HMB dimin-
ishes quality-of-life and has adverse impact on employment and fam-
ily/caring roles [68]. In otherwise healthy mid-age women, the
morbidity due to HMB is often underestimated, whereas the cumula-
tive impact on quality of life (QOL), over 30 days per year, would be
unacceptable in most other health conditions [7,9]. Menstruation is
acknowledged globally as incurring costs that exacerbate poverty.
Hence some recent government initiatives to encourage/fund provi-
sion of free menstrual protection [7,10].
Current management of symptom of HMB is generic and includes
conservative, medical or surgical approaches (endometrial ablation
and hysterectomy). There are diverse potential mechanisms for HMB
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error [8,9,12]. In routine clinical practice, particularly primary care, first
line treatment is usually medical therapy (hormonal or non-hormonal)
but this may be found to be ineffective, or may not be tolerated, for
example on account of common side effects of hormonal treatments
[6,9,12]. In the UK NHS HMB Audit (20122013) of hospital gynaecology
clinic healthcare (n = 8183) it was reported that oral medication, LNG-
IUS and surgery were received within the follow-up year by 29%, 33%
and 43%, respectively, of patients newly attending hospital outpatient
gynaecology clinics, while 18% received no treatment [13].
No novel medical treatment for HMB has been developed for near
20 years, no time-specific (non-hormonal) treatment for at least 30
years. An established highly effective treatment for HMB is the con-
traceptive levonorgestrel-releasing intrauterine system (LNG-IUS;
available since 1995, licensed for HMB in 2001) [3,6,9,12]. However,
the LNG-IUS is unsuitable for women desiring pregnancy (as are sys-
temic progestin therapies) and 17% of women receiving LNG-IUS for
HMB were dissatisfied with this treatment [3].
A 2013 systematic review of non-surgical treatments for HMB
found that trials of non-hormonal medical treatments for HMB were
completed in the main over two decades ago, before 1996, and gener-
ally imposed an entry criterion of objectively assessed average base-
line menstrual blood loss volume (MBL) exceeding 80 mL [12]. The
medical treatments reviewed showed good percent reductions in
measured MBL volumes, for treatment compared to baseline or pla-
cebo (26% to 54% reduction for anti-fibrinolytics, 20% to 52% for
NSAIDs) [12]. However, when prescribed for HMB in routine clinical
practice, patients very often report these treatments as being or soon
becoming insufficiently effective [6,9].
The 2012 UK NHS HMB Audit found that at one year after index
attendance at gynaecology clinic, over a third of women (36%) were
‘unhappy’ or ‘very unhappy’ with their ongoing HMB symptoms [13].
Furthermore, by this point there had been a switch to different treat-
ment (possibly surgical), by over half those starting with oral medica-
tion, and by one third starting with IUS [13]. Alternative treatment
options for HMB are needed for surgical intervention to be avoided
and fertility/ uterus preserved. This highlights the urgent need for tar-
geted medical treatment for the debilitating symptom of HMB, that is
effective, that does not have unacceptable side effects, and that can
be used longish-term, even while seeking to become pregnant.
Endogenous glucocorticoids inhibit angiogenesis [14]. Regulation
of endometrial blood vessel function is required to limit endometrial
bleeding and menstrual blood loss [15]. Local endometrial glucocorti-
coid deficiency may, therefore, result in increased menstrual blood
loss. We have demonstrated that endometrium from women with
HMB has increased luteal phase expression of 11bhydroxysteroid
dehydrogenase type 2 (11bHSD2), an enzyme which inactivates cor-
tisol (the major glucocorticoid) [14]. We thus hypothesised that "res-
cue" of luteal phase endometrial glucocorticoid deficiency, at an early
stage of endometrial repair/angiogenesis, would improve endome-
trial (spiral arteriole) blood vessel differentiation, augment local
blood vessel vasoconstriction at onset of menses, and reduce volume
of menstrual bleeding [1416]. Dexamethasone was selected for use
because it is not inactivated by 11bHSD2, but converted to 11-dehy-
dro-Dex which remains bioactive.
We then conducted a small “proof of concept” animal study,
which provided highly supportive evidence for reduction in volume
of menstrual bleeding with dexamethasone (a cortisol surrogate/ glu-
cocorticoid receptor agonist), administered in the luteal phase several
days prior to expected menses. (see Supplement A)
This dose-finding study aimed to determine (i) if dexamethasone
administered to women seeking treatment for the symptom of HMB
is safe, acceptable and efficacious, and (ii) the optimal dose from
those tested. A Bayesian adaptive trial was designed, requiring partic-
ipation of substantially fewer women than a traditional multi-arm
randomised trial [16,17].2. Methods
2.1. Study design
The randomised controlled trial Dexamethasone For Excessive
Menstruation (DexFEM), undertaken in Lothian, Scotland, had a
Bayesian response-adaptive parallel group design, comparing six
doses of oral dexamethasone treatment and placebo. The full protocol
is available [dx.doi.org/10.17504/protocols.io.bpw3mpgn] and we
have published details of the trial design (Study 3 in protocol) [16],
and of preliminary simulation studies to develop the adaptive
trial [17] (Or see supplements F, H, I).
2.2. Ethics
The trial received favourable ethical opinion from Scotland A
Research Ethics Committee (12/SS/0147), clinical trial authorisation
from the UK Medicines and Healthcare products Regulatory Agency
(MHRA ref 01384/0226/0010001), and was registered with Clinical-
Trials.gov [NCT01769820] and EudractCT (201200340598). All
patients received full study information and opportunity for ques-
tions/discussion before providing written research consent.
2.3. Participants
The study population was women aged 18 years and over wishing
treatment for the symptom of HMB. The main exclusion criteria were
intending trying for pregnancy in the next five months, average cycle
length outside 21 to 42 days, menstrual periods ‘very irregular’,
breastfeeding, pregnancy ‘possible’ but unwilling to use contracep-
tion, diabetes mellitus, previous or current cancer of cervix/uterus/
ovary/breast, and seven prohibited medications including taking sys-
temic, inhaled or potent topical glucocorticoid treatments in the last
month [16]. (See Supplement B.1) If a woman eligible as above wished
to participate, a further eligibility criterion was average MBL over
two screening menstrual periods equal to or exceeding 50 mL. MBL
was assessed by objective validated laboratory measurement of col-
lected used sanitary protection, by modified alkaline-haematin
method [18].
We recruited from: National Health Service Lothian (NHSL) hospi-
tal gynaecology clinics and community gynaecology clinic; from
Lothian primary care through mail-out by Scottish Primary Care
Research Network (SPCRN) [16]; and by media advertising. Subse-
quently we added recruitment facilitated by SHARE (Scottish Health
Research Register of over 200,000 people who had agreed to receive
invitations for research studies selected as of potential interest using
data in their NHS records), and via three study advertisements dis-
played on Facebook to women in the relevant age range and our geo-
graphical location.
Clinic recruitment involved clinicians informing women who
reported symptoms of HMB, attending a NHSL community gynaecol-
ogy clinic or gynaecology outpatient department, about the research,
and if interested, providing full written information [16]. Similarly,
any woman from other recruitment routes who contacted the
research team about the ‘advertised’ research, was sent full study
information. Women given study information were contacted by
telephone after about a week, and if the decision was to participate, a
research screening appointment was scheduled at Royal Infirmary
Edinburgh gynaecology department. After informed consent had
been confirmed by study doctor, or occasionally delegated hospital
gynaecologist, eligibility was assessed, including a full menstrual,
medical history and pelvic examination. This included ultrasound
(USS) if uterine enlargement was found and there was no prior rele-
vant USS (within six months). Classification of potential aetiologies
underpinning the symptom of HMB was evaluated as part of this
assessment [11].
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We planned to randomise 108 women. Allocation to placebo was
28.6% (2/7) throughout. The six dexamethasone doses (0¢4 to 1¢8 mg
daily, split morning and evening) started with equal allocation proba-
bilities (11¢9% each). At each of five adaptations (triggered at 16, 32,
50, 66, and 84 randomisations), we used interim analysis, based on
accumulating primary outcome data, to re-calculate allocation proba-
bilities to favour dexamethasone doses which would provide most
information on the underlying dose-response curve. A normal
dynamic linear model (NDLM) of the primary outcome was used to
predict, for each dexamethasone dose, the amount of information
about the dose-response curve that would be gained if the next
patient were randomised to that dose [17]. This was quantified as the
reciprocal of the predicted variance (ie precision) of the primary out-
come at the current estimate of the ED95 dexamethasone dose (the
dose with 95% of the maximum efficacy). Subject to approval by the
independent Data Monitoring Committee (DMC) who oversaw the
trial, the set of dexamethasone dose randomisation probabilities was
then updated, to be proportional to the predicted increase in infor-
mation to be gained were a patient to be randomised to each dose.
(See Supplements F, D.2)
Computer-generated pseudo-random numbers were used to gen-
erate the randomised allocation sequence. No stratification or block-
ing was used. Randomisation probabilities resulting from the
adaptation analyses were communicated, by the unmasked statisti-
cian, only to the trials unit programmer responsible for updating the
web-based randomisation system. Bulk supplies of encapsulated pla-
cebo and dexamethasone were held by NHSL hospital pharmacy who
dispensed trial medication in bottles labelled with a unique random-
isation number from the list provided by Edinburgh Clinical
Trials Unit.
Encapsulation of placebo and dexamethasone in identical hard
gelatine capsules ensured participants and clinical staff were maskedFig. 1. Participant time-line in study  5 to 6 months from screening appointmentto allocations. Enrolment and accessing the web-based randomisa-
tion system were undertaken by members of the study clinical
research team, which ensured allocation sequence was concealed
from researchers, clinical staff, and participants. Only the DMC, the
trials unit statistician producing the DMC reports, and pharmacy staff
dispensing the study medication were aware of treatment allocations
during the trial.
2.5. Procedures
The intervention was placebo or one of 6 doses of (licensed) syn-
thetic glucocorticoid dexamethasone (manufactured by Tayside Phar-
maceuticals, Dundee), taken orally twice-daily for five days in the
luteal phase of three menstrual cycles. It was judged that, for opti-
mum vascular benefit, treatment should commence nine days before
the next menstrual period, which generally starts 15 days after ovula-
tion. Urine dipstick-testing was to be commenced day seven of the
cycle, expecting a positive result (urine evidence of luteinizing hor-
mone (LH) surge) to precede ovulation by about 12 h, and next men-
strual period by 16 days. Each participant was given a supply of her
allocated intervention at the start of cycle, notified the research team
when positive dip-stick result occurred, and self-administered treat-
ment regimen was scheduled to start seven days later. If no LH surge
was detected, or if serial urine testing was not carried out, treatment
start was calculated by counting back from cycle-date-history-pre-
dicted start of next period. (See also Supplement B.2) Clinical caution
meant DexFEM participants had to conduct a pregnancy test each
cycle. Women were reminded by text message when to start dip-
stick-testing, and when to start medication, including a reminder
that treatment start was subject to a negative pregnancy test. Partici-
pants were also asked to record study medication intake and to
return all unused study medication.
In addition to data collection at recruitment, Fig. 1 shows there
was assessment of each study menstrual period, overview
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and a follow-up clinic appointment 30 days after last treatment.
2.6. Outcomes
Primary outcome was change from baseline in laboratory-assayed
MBL i.e. given there was no MBL collection in first treatment phase,
average MBL of second and third treatment phase periods minus
average of two screening periods. Secondary outcomes included data
collected via (i) Treatment Review Questionnaire completed after last
treated menstrual period, assessing satisfaction with treatment, and
(ii) diary reports women completed during and at end of each study
period (two baseline, three treatment phase). The five diaries also
allowed, for each treatment phase, calculation of change from base-
line in semi-quantitative (pictogram-diary-derived) estimate of vol-
ume of menstrual period [19]. Subjective outcomes collected
contemporaneously in treatment phase diaries were: heaviness of
period, and comparison of this period to ‘before trial’ regarding:
heaviness, period pain, feeling generally well, impact of period on
daily activities, and period being a ‘problem’. The Treatment Review
Questionnaire, completed after third treated period, collected overall
treatment phase outcomes: self-reported ‘lighter’ or ‘much lighter
bleeding’, generally 'feeling much better during periods', improve-
ment in period pain ('less' or 'much less severe'), and acceptability of
treatment.
2.7. Statistical analysis
A detailed statistical analysis plan (SAP) was written while
blinded to randomised treatment allocations, prior to study database
lock (see Supplement E). For all outcomes, analysis was by allocated
groups, for all data provided. The dose-response curve for the pri-
mary outcome was analysed in WinBUGS using a Bayesian second
order NDLM [17], adjusted for the screening MBL measurements of
each woman. The NDLM is flexible and requires few assumptions
about the shape of the underlying dose-response curve [17]. For eachFig. 2. CONSORdexamethasone dose, a 95% credible interval (CrI) was then calcu-
lated for the mean difference in MBL change (dexamethasone minus
placebo). Using non-informative priors, the posterior probability of
efficacy against placebo was calculated for each dose. (See Supplement
C). Change from baseline in menstrual diary pictogram scores (aver-
age of three treatment phase periods minus the average of two
screening periods) was analysed as for primary outcome. Binary sec-
ondary endpoints were derived from Treatment Review Question-
naire ‘satisfaction with treatment’ items and from diary subjective
reports, and these were analysed using Bayesian comparison of pro-
portions for each dexamethasone dose versus placebo. A 95% credible
interval was calculated for the difference in proportions (dexametha-
sone minus placebo).
On the basis of simulations, a sample size of 100 was estimated to
have statistical power of 93¢8%, assuming: within-patient standard
deviation of 18 mL for MBL (unpublished data); mean MBL benefit for
treatment over placebo is at most 16 mL; and a range of plausible
shapes of dose-response curves (steep incline, slowly ascending,
inverted U-shape). The target enrolment total was set at 108 to allow
for withdrawals/loss to follow-up.2.8. Role of funder
The funder of the study (MRC) had no role in study design, data
collection, data analysis, data interpretation, or writing of the report.
The writing group (including corresponding author) had full access
to all the data in the study and had final responsibility for the deci-
sion to submit for publication.3. Results
Recruitment (screening appointment) ran from 29/1/2014, to 25/
9/2017, ensuing randomisations (to all groups) continued until
November 2017, and final follow-up was March 2018. Fig. 2 presents
the participant flow for the study. (See also Supplement D.1)T diagram.
Table 1




[min, Q1, Q3, max]*
Median
[min, Q1, Q3, max]*
Age (years) 43 [21, 38, 46, 53] 43 [21, 37¢5, 47, 54]
Response when asked how
long HMB has been a
problem (years)
5 [1, 3, 11, 33] 5 [0¢5, 2, 14, 37]
Minimum duration of
menses in previous 3
months (days) **
5¢5 [3, 5, 7, 15] 5¢0 [2, 4, 6, 14]
Maximum duration of
menses in previous 3
months (days) **




[51, 63¢5, 206, 677¢5]
136¢0
[50, 84, 187, 479¢5]
Approx. years since last
pregnancy (if
applicable***)
6 [2, 5, 9, 24] 11 [0, 6, 15, 31]
Weight (kg) 69¢2 [48, 60¢9, 91, 129] 74¢4
[46, 64¢8, 85¢2, 124]
Units of alcohol consumed
per week currently
1 [0, 0, 6, 16] 3 [0, 0¢5, 10, 40]
Mean (SD) Mean (SD)
Age at menarche (years) 12¢6 (1¢4) 12¢8 (1¢5)
Systolic blood pressure (mmHg) 122¢0 (13¢4) 124¢9 (12¢3)
Diastolic blood pressure (mmHg) 76¢1 (13¢3) 77¢2 (10¢1)
Minimum cycle length past 3 months (days) 26¢4 (2¢7) 26¢0 (2¢6)
Maximum cycle length past 3 months (days) 30¢5 (4¢4) 29¢8 (3¢5)
Placebo Dexamethasone
N 27 80
n % n %
Ethnicity
White 26 96% 73 91%
Mixed 0 1 1%
Asian 0 3 4%
African 1 4% 1 1%
Caribbean 0 1 1%
Not disclosed 0 1 1%
No. of births
None 10 37% 25 31%
1 3 11% 16 20%
2 9 33% 22 27%
3 4 15% 13 16%
46 1 4% 4 5%
No. of miscarriages
None 17 63% 59 74%
1 7 26% 15 19%
24 3 11% 6 8%
No. of terminations
None 22 81% 63 79%
1 3 11% 11 14%
2 2 7% 5 6%
3 0 0
4 0 1 1%
Response when asked if has painful periods
Yes 21 78% 58 73%
No 6 22% 22 27%
Fibroids present
No recent USS/MRI 1 4% 5 6%
No fibroids detected 16 59% 41 51%
Fibroid < 3 cm 8 30% 25 31%
Fibroid >= 3 cm 2 7% 9 11%
Smoking history
Current (1 to 20 per day) 6 22% 8 10%
Previous 3 11% 19 24%
Never 18 67% 53 66%
* min = minimum, Q1 = 1st quartile, Q3 = 3rd quartile, max = maximum.
** 2 with missing data, one Placebo, one dexamethasone.
*** 78 women had been pregnant, with 19 allocated to placebo, and 58 to
Dexamethasone.
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50 mL average MBL inclusion criterion, leaving 107 women to be
randomised. After the final adaptation, the allocation across arms
was as shown in the randomisation row of Fig. 2. (See also Supplement
D.2) Ninety-six of 107 (90%) completed the trial, 97 (91%) providing
primary outcome data. Across the three treatment phases adherence
was 86% (89/103), 90% (88/98), and 79% (76/96), respectively. There
were five protocol violations; one resulted in withdrawal, for ineligi-
bility, before start of treatment. (See also supplement D.3).
Participants were aged 21 to 54 years and self-reported HMB had
been a problem for six months to 37 years (Table 1). A quarter of
women reported their periods lasting more than six days, 33% of
women were nulliparous and 74% had painful periods. The predomi-
nantly white ethnicity (93%) reflects 2014 NHS Lothian Health Board
data for the region, for females aged 1849 years (92%). The partici-
pants in placebo and dexamethasone groups had very similar base-
line characteristics and were generally comparable in terms of
medical history. (See also Supplement D.4).
For those with primary outcome data, treatment groups placebo
(n = 24) and (overall) active (n = 73) had, respectively, medians of
average screening MBL 105 and 132 mL (maxima 384, 480 mL).
The lower half of Table 2 reports the NDLM results for primary
outcome, separately by dose. Fig. 3 shows some treatment advantage
in all dose groups, but that the greatest treatment benefit was in the
1¢8 mg total daily dose  a treatment reduction in MBL of 25 mL,
with 95% credible interval 1 to 49 mL. This dose had posterior proba-
bilities, of 0¢98 and 0¢89 respectively, for any advantage over placebo,
or at least a 10 mL advantage.
Secondary outcome menstrual volumes calculated from men-
strual diaries[19], available for 25 women on placebo, 74 on dexa-
methasone, showed similar treatment effects to the primary MBL
outcome. The estimated advantage for the 1¢8 mg dose over placebo,
for change in mean volume from screening to treatment, was a 32 mL
reduction in blood loss (95% CrI 69 mL reduction to 4 mL increase),
with posterior probability of any advantage over placebo of 0¢96. (See
also Supplement D.5)
For women’s secondary outcome menstrual diary subjective
assessments for each treatment phase, see Supplements D.6-D.8.
Regarding final overview assessment by Treatment Review Question-
naire, Fig. 4 shows, for dexamethasone dose versus placebo, posterior
median differences in proportions reporting more favourable dichot-
omized responses (most recent period compared to before trial).
Comparing placebo and dexamethasone groups, similar proportions
expressed willingness to keep taking the treatment if it were avail-
able for HMB, but without the need for dip-stick testing: 44% (11/25)
and 45% (32/71) respectively.
There were three serious adverse events (AEs): two in screening
phase, and one post-randomisation, in a woman receiving placebo.
There were no suspected unexpected serious adverse reactions. Over-
all, 73 women (71% of 103 receiving treatment) had at least one AE,
with rates lower for placebo (15, 58%) than dexamethasone (58, 75%).
No patient was withdrawn on account of AEs. (See also Supplement
D.9).
4. Discussion
Our trial found greater reduction in menstrual blood loss volume
with dexamethasone than placebo, especially at highest dose of
0¢9 mg twice-daily, which showed mean reduction in MBL of 25 mL
(CrI 1 mL to 49 mL) (Fig. 3). These findings are consistent with our
glucocorticoid-deficiency hypothesis, that locally available endome-
trial cortisol may be necessary for optimal endometrial blood vessel
maturation, to limit menstrual blood loss [1416].
Methodological challenges in menstrual research are pertinent.
Participants had thorough assessment of HMB symptoms and of eligi-
bility, prior to recruitment. This included those with uterine fibroids
Table 2
Primary outcome change in MBL: data summaries and statistical modelling.
Randomised Treatment
Placebo Dexamethasone Total dose Dexamethasone (split twice daily)
(any dose) 0¢4 mg 0¢8 mg 1¢0 mg 1¢2 mg 1¢5 mg 1¢8 mg
DATA SUMMARIES
N 24 73 5 9 21 8 14 16
Mean change in MBL* (mL) 6¢0 20¢9 7¢8 23¢8 18¢5 5¢8 24¢5 36¢7
SD 51¢3 44¢0 54¢3 41¢7 37¢8 50¢6 31¢5 53¢8
Minimum 170 188 66¢0 92¢0 143 58¢5 85¢5 188
Maximum 97¢0 89¢5 75¢5 37¢0 47¢5 89¢5 35¢0 27¢0
NDLM-MODELLED TREATMENT EFFECTS
Posterior median for difference (dexamethasoneminus placebo) in mean MBL change (mL)** 3 12 8 4 15 25
95% CrI *** (mL) 28, 23 41, 9 29, 13 28, 24 37, 8 49,1
Posterior probability of at least a 10 mL dexamethasone advantage over placebo 0¢26 0¢58 0¢42 0¢32 0¢67 0¢89
Posterior probability of any advantage of dexamethasone over placebo 0¢64 0¢86 0¢78 0¢63 0¢90 0¢98
* Negative values for ‘mean change’ in primary outcome indicate treatment advantage over placebo. MBLs were laboratory-assessed in only the 2nd and 3rd treatment
phases, but eight women provided only one MBL collection (six missing the 2nd treatment phase MBL, two the 3rd). For these the single MBL laboratory assessment
obtained was analysed.
** From NDML model of individual mean MBL change (from screening baseline to treatment phase),with adjustment for individual average baseline MBL.
*** CrI credible interval.
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local impact of glucocorticoid in the endometrium, there are no
research findings to date suggesting that uterine structural features,
for example, fibroids, disturb glucocorticoid signalling pathways.
MBL assessment is the preferred outcome for HMB drug trials,
despite requiring laboratory infrastructure and larger research bud-
get, and that it may deter participation. HMB treatment trials gener-
ally utilise an entry criterion of 80 mL mean screening MBL, a value
that represents the upper 5% point of the distribution of MBL volumes
in a Scandinavian community study undertaken in 1960, which is not
necessarily an appropriate contemporary threshold for HMB war-
ranting clinical intervention [20]. In a large US trial this threshold
was failed by 71% of the 711 potential HMB trial participants [21].Fig. 3. Primary outcome results: Posterior median difference, for each dexamethasone dose g
Legend: Primary outcome is change in assayed MBL for an individual i.e. their treatment phase M
ing MBL of each participant.Furthermore, laboratory measured MBL assessment is very rarely
undertaken in routine clinical practice, so many women requesting
treatment for HMB might not have average measured MBL exceeding
80 mL over two/three periods, as used in HMB trials. Thus it is
unknown how well the trial-established evidence for contending
medical treatments applies to many women being treated for prob-
lematic HMB. Diverse aetiologies are hypothesized for HMB [8,11],
and HMB research is beset with many outcome measures [22]. HMB
is seldom the only troubling symptom being experienced so there are
heterogeneous presentations of HMB [1,18,23,24]. Therefore reduc-
tion in MBL volume might not necessarily be a sufficient indicator of
treatment ‘success’ [20]. Subjective assessment of treatment effect
might be more pertinent, or assessments (plural) might allow a moreroup minus placebo, in change in menstrual blood loss volume (mL), Rogue and 95% CrI
BL screening MBL. Normal dynamic linear model of change in MBL is adjusted for Screen-
Fig. 4. Treatment Review Questionnaire secondary outcome results: Difference in proportions responding as indicated - for each dexamethasone dose minus placebo - and 95% CrI
Legend: The left-panel items ask participant to compare their most recent menstrual period (3rd), to before the trial, while the right-panel items ask for 'absolute' judgements. Estimates
plotted in shaded area favour dexamethasone, while those plotted in unshaded area, favour placebo.
Left panel n = 97, 95, 97 respectively, and right panel n = 97, 95, 96.
8 P. Warner et al. / EBioMedicine 69 (2021) 103434holistic picture and give more interpretable results [20]. Treatment
effect reported as absolute reduction in MBL volume might not be
informative for women. Lukes et al. found that while the threshold
for patient-perceived meaningful absolute reduction differed with
baseline MBL (i.e. 20 mL threshold for baseline MBLs 80 to 160 mL,
but 56 mL for baseline MBL over 160 mL), a meaningful relative
reduction was 22% of baseline MBL regardless of baseline volume [25].
Reliability of measurement of ‘objective‘ MBL depends on complete-
ness of menstrual collection, and optimum laboratory protocols for
assay method. Pictogram diary assessment is more acceptable to par-
ticipants, but its validity and reliability depends on conscientious and
careful diary completion. HMB trials seldom use diaries to assess
menstrual volume, very rarely diaries only, perhaps due to concern
that performance observed in method validation studies (such as
[19]) would not be achieved without parallel MBL assessment.
Some strengths of our trial are as follows. We have demonstrated
the feasibility of an adaptive randomisation trial for HMB. Adaptive
designs require substantial preliminary development work but they
enable efficient learning about dose response, and they estimate
treatment effects with improved precision [26,27]. MBL data is avail-
able within 2 weeks of luteal phase treatment, and hence well-suited
to adaptive trials, which work best where outcome data is available
soon after treatment, for earliest possible inclusion into the next
adaptation analysis [26]. There was excellent retention through five
menstrual cycles of screening and treatment, despite the demands on
participants of MBL collection, and urine dip-stick testing. Support of
participants by experienced research nurses, via mobile phone con-
tacts, in particular regarding start dates, ensured provision of primaryoutcome data by 91% of participants (97/107). Our lower MBL eligibil-
ity threshold (50 mL) means DexFEM trial participants are more rep-
resentative of patients with clinical need for treatment of HMB, than
in most published HMB trials. Outcome assessment included both
objective and semi-quantitative assessment of MBL, and subjective
assessment of effect of treatment on a range of aspects of periods,
including volume. The observed dose-response pattern for picto-
gram-estimated MBLs was very similar to that for objectively
assessed MBL, albeit less marked. These diary MBL assessments
ensured we had some assessment of volume of the first treatment
phase period, where there was no laboratory MBL assessment, and
will allow further methodological analyses. Given dexamethasone is
already licensed, there is no need for safety/tolerability studies in
healthy volunteers, offering the potential for accelerated translation
from pre-clinical to clinical studies. In our trial there were only 3 seri-
ous adverse events, none occurring on/after active treatment, and no
patient was withdrawn on account of adverse events.
Some limitations in DexFEM are as follows. The trial time-line had
to be extended to achieve target recruitment, so adding new sources
of participants means there was potential for case mix change across
time, which could raise concerns in relation to ‘adapting’ (changing)
randomisation probabilities. However, the randomisation process
ensured contemporaneous (placebo) controls across the entire study.
Typical within-woman variation in cycle lengths, particularly
amongst those aged over 45 years, means that counting cycle days to
schedule treatment is unreliable, while mid-cycle daily dipstick-test-
ing to identify LH surge is burdensome. Experience tells us that a pro-
portion of women decline trial participation if submission of used
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ple. Diversity in mean baseline MBL (which for DexFEM participants
ranged from 50 to 677¢5 mL) may reduce overall precision of estima-
tion of dexamethasone treatment effect. Similarly, diversity in con-
comitant menstrual symptoms could distort subjective assessment of
treatment effect, for specific subgroups.
We used a lower than usual MBL threshold for eligibility (50 mL),
and only 28% of participants recruited for DexFEM failed this crite-
rion. The DexFEM trial sample was therefore representative of
patients with clinical need for treatment of HMB i.e. heterogeneous
in terms of presentation, concomitant menstrual symptoms, baseline
MBL, duration of problem, parity, and in some cases presence of mod-
erate-sized uterine fibroids.
Our findings support a glucocorticoid-deficiency hypothesis for
HMB, but it is possible dexamethasone may be having a pharmaco-
logical effect independent of endogenous glucocorticoid action. A
dose of 0¢75 mg Dexamethasone once every day is considered to pro-
vide physiological replacement that is similar, for example, to pred-
nisolone 5 mg once daily. Dexamethasone was well tolerated, with
79% to 90% of participants taking all of their allocated treatment in
each treatment phase, and no serious AEs occurred with active treat-
ment. However, chronic use of glucocorticoids at supra-physiological
doses is associated with a higher incidence of cardiovascular disease
[28] and fracture [29] as well as risks from suppression of endoge-
nous cortisol secretion. There is thus a tension between reversing an
hypothesised local endometrial deficiency in cortisol (to ensure ade-
quate luteal phase local glucocorticoid for endometrial blood vessel
maturation necessary to limit menstrual blood loss) and minimising
cumulative systemic glucocorticoid dose. Our regimen comprised
very short-term administration of Dexamethasone, for just five days
during the luteal phase of each menstrual cycle.
One potential advantage of dexamethasone management of HMB
is that it might be licensed for women with HMB seeking to control
symptoms while trying for pregnancy. In the general population,
women may conceive while using regular steroid medications for
(non-HMB) medical indications, often at higher doses than used in
DexFEM. The administration of steroids in very early pregnancy has
been reviewed [30] including administration early for the treatment
of recurrent miscarriage. The daily doses typically used for preven-
tion of miscarriage, usually for the entire first trimester, are equiva-
lent to twice to three times the daily doses used in DexFEM, and HMB
treatment as per DexFEM would persist for only five days of the sin-
gle cycle in which conception occurs.
The dose of dexamethasone with the maximum effect on MBL was
0¢9 mg (twice daily). This showed an average relative reduction in
MBL volume of 19% of individual screening MBL, which is close to the
published finding that 22% of baseline MBL is a ‘meaningful’ relative
reduction [25]. However, we found dexamethasone had no apparent
beneficial effect on period pain (Fig. 4), a symptom strongly associ-
ated with HMB complaint [1,18].
Dexamethasone treatment for the symptom of HMB shows con-
siderable promise as a treatment option, one that might be welcomed
by women who eschew surgical treatment, experience unacceptable
side-effects with hormonal treatment, or wish to try for pregnancy.
Future longer-term studies will be required to establish that the sys-
temic dexamethasone regimen used would not induce the known
adverse effects of dexamethasone use. Local delivery of dexametha-
sone#, targeted to the required site of action, could reduce the dose
required, and hence systemic levels, allaying concerns regarding
cumulative doses of dexamethasone across time. Intrauterine deliv-
ery of dexamethasone could be achieved by adapting existing intra-
uterine delivery methods, although this would mean continuous
administration. Intravaginal modes of site-targeted delivery would
allow short-term intervention preceding onset of menses which
could substantially reduce dose delivered. Further investigations (e.g.
N-ofone studies) could aid investigation of these alternativeregimes, and of critical timings for effective dexamethasone adminis-
tration. Studies exploring consistency of dexamethasone benefit
according to presentation and underlying aetiology for the HMB
would be invaluable in enhancing understanding of mechanisms.
HMB has substantial adverse impact on the quality-of-life of indi-
viduals affected, their families and society[1,2,48,10,24], and HMB
can exacerbate anaemia and iron deficiency [6,18]. Women often
have years of quality-of-life deficit before seeking professional help
for HMB[1], because they do not wish to take hormone treatment
and decline surgical treatments which may impair future fertility.
Amongst DexFEM participants the median duration of HMB, so far,
was five years. In the past 20 years there have been no new medical
approaches for HMB treatment, yet the options currently available
are all too often found wanting [3,6,9,12,13]. There remains unmet
need for medical therapies that have fewer unacceptable side effects.
We have completed an adaptive randomised controlled trial, of a
new medical therapy for the symptom of heavy menstrual bleeding,
the first for over two decades. The findings, generalisable to the range
of women seeking treatment for HMB, show that 0¢9 mg of dexa-
methasone twice daily for five days in the luteal phase, reduces
objectively-measured MBL volume. Further developmental and con-
firmatory research is warranted.Contributors
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